[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SK126595A3 - Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid - Google Patents

Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid Download PDF

Info

Publication number
SK126595A3
SK126595A3 SK1265-95A SK126595A SK126595A3 SK 126595 A3 SK126595 A3 SK 126595A3 SK 126595 A SK126595 A SK 126595A SK 126595 A3 SK126595 A3 SK 126595A3
Authority
SK
Slovakia
Prior art keywords
hyaluronic acid
component
angiogenesis
disease
condition
Prior art date
Application number
SK1265-95A
Other languages
English (en)
Slovak (sk)
Inventor
Derek A Willoughby
Chandan Alam
Samuel S Asculai
Rudolf E Falk
David W Harper
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of SK126595A3 publication Critical patent/SK126595A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Filters For Electric Vacuum Cleaners (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cephalosporin Compounds (AREA)
SK1265-95A 1993-04-16 1994-04-15 Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid SK126595A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002094203A CA2094203A1 (en) 1993-04-16 1993-04-16 Inhibition of angiogenesis
PCT/CA1994/000207 WO1994023725A1 (en) 1993-04-16 1994-04-15 Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid
CN94192096A CN1123005A (zh) 1993-04-16 1994-04-15 用于抑制、控制和消退血管生成的含有透明质酸和nsaid的组合物

Publications (1)

Publication Number Publication Date
SK126595A3 true SK126595A3 (en) 1997-03-05

Family

ID=37089291

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1265-95A SK126595A3 (en) 1993-04-16 1994-04-15 Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid

Country Status (18)

Country Link
EP (1) EP0695187B1 (no)
JP (1) JPH08508505A (no)
CN (1) CN1123005A (no)
AT (1) ATE226827T1 (no)
AU (2) AU694113B2 (no)
BR (1) BR9405781A (no)
CA (1) CA2094203A1 (no)
CZ (1) CZ267995A3 (no)
DE (1) DE69431623D1 (no)
FI (1) FI954914A (no)
HU (2) HUT74462A (no)
IL (1) IL109293A (no)
NO (1) NO954073L (no)
PL (1) PL306806A1 (no)
SG (1) SG48924A1 (no)
SK (1) SK126595A3 (no)
WO (1) WO1994023725A1 (no)
ZA (1) ZA942597B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
EP2298300A1 (en) * 1996-11-05 2011-03-23 The Children's Medical Center Corporation Compositions for inhibition of anglogenesis comprising thalidomide and aspirin
WO1998042329A1 (fr) * 1997-03-21 1998-10-01 Mitsubishi Chemical Corporation Preventifs et/ou remedes destines a des affections provoquees par une neovascularisation anormale
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
ATE376824T1 (de) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
JP4587148B2 (ja) * 2000-03-24 2010-11-24 生化学工業株式会社 平滑筋細胞増殖促進剤
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
ITPD20020003A1 (it) * 2002-01-11 2003-07-11 Fidia Advanced Biopolymers Srl Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
ITMI20040347A1 (it) * 2004-02-26 2004-05-26 Pharma Medical Ltd Nuovo farmaco di associazione
CN101287474B (zh) 2005-07-27 2014-08-20 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
CN101287475B (zh) 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
EA015702B1 (ru) * 2007-05-28 2011-10-31 Винченцо Массимо Ломбардо Противовоспалительная и анальгетическая композиция для местного применения в области опорно-двигательного аппарата животного
EP2567697A1 (en) * 2011-09-12 2013-03-13 Almirall, S.A. Topical pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids

Also Published As

Publication number Publication date
IL109293A (en) 1999-01-26
AU6561694A (en) 1994-11-08
SG48924A1 (en) 1998-05-18
DE69431623D1 (de) 2002-12-05
EP0695187B1 (en) 2002-10-30
IL109293A0 (en) 1994-07-31
BR9405781A (pt) 1996-01-16
AU6994198A (en) 1998-07-23
PL306806A1 (en) 1995-04-18
EP0695187A1 (en) 1996-02-07
CN1123005A (zh) 1996-05-22
HU211954A9 (en) 1996-01-29
ATE226827T1 (de) 2002-11-15
AU694113B2 (en) 1998-07-16
NO954073L (no) 1995-12-04
JPH08508505A (ja) 1996-09-10
FI954914A (fi) 1995-11-06
HU9500113D0 (en) 1995-03-28
FI954914A0 (fi) 1995-10-16
CZ267995A3 (en) 1996-10-16
CA2094203A1 (en) 1994-10-17
NO954073D0 (no) 1995-10-13
HUT74462A (en) 1996-12-30
ZA942597B (en) 1995-02-08
WO1994023725A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
DE69330180T2 (de) Hyaluronsäure enthaltende formulierungen
US5639738A (en) Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2122519C (en) Cancer treatment and metastasis prevention
DE69034018T2 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69333072T2 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
SK126595A3 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid
US20110124596A1 (en) Composition for treating inflammatory diseases
WO1996006622A1 (en) Hyaluronic acid and derivatives for modulation of cellular activity
US6114314A (en) Formulations containing hyaluronic acid
US5847002A (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
HU211698A9 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
CA2121454A1 (en) Inhibition, control and regression of angiogenesis
CA2167044C (en) Oral administration of effective amounts of forms of hyaluronic acid
TW316236B (no)